HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on ALX Oncology Holdings (NASDAQ:ALXO) and maintained a price target of $25.
August 01, 2024 | 1:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on ALX Oncology Holdings and maintained a price target of $25.
The reiteration of a Buy rating and the maintenance of a $25 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively impact ALXO's stock price in the short term. This indicates continued confidence in the company's performance and potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100